CSE:PHRX - Post Discussion
Post by
Betteryear2 on Apr 01, 2022 8:28am
Pharmadrug Advances PD-001
- Committed to the 'pipeline-in-a-pill' approach with PD-001 for certain cancers and COVID-19
- Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute
- Receives final positive data for recently conducted prostate cancer model and evaluates opportunities to broaden claim set for PD-001 in the treatment of cancer
- Initiates IND-enabling efficacy study of PD-001 to treat esophageal cancer
- Evaluates opportunities to deepen and broaden testing of PD-001 as a broad-spectrum oral antiviral
Toronto, Ontario--(Newsfile Corp. - April 1, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to provide an update on multiple activities currently underway which support the Company's 'pipeline-in-a-pill' approach in the development of PD-001, its patented, orally bioavailable version of cepharanthine for the treatment of cancer and infectious disease.
Be the first to comment on this post